top of page
Understanding and Preventing the Global Increase of Inflammatory Bowel Disease
GG Kaplan and SC Ng, Gastroenterology. 02, 2017. 152: p. 313-321.e312. [IF: 18.392] The are contemporary conditions of industrialized societies. The global spread of inflammatory bowel diseases (IBDs) appears to associate with Westernization of diets and environments, which affects the intestinal microbiome and increases the risk of IBD in genetically susceptible individuals. It is important to increase our understanding of these events to slow progression of IBD. We present
Emerging Biologics in Inflammatory Bowel Disease
HCH Chan and SC Ng, 1. Journal of Gastroenterology. 02, 2017. 52: p. 141-150. [IF: 0.165] Early biologic therapy is recommended in patients with inflammatory bowel disease and poor prognostic factors and in those refractory to conventional medications. Anti-tumor necrosis factor (anti-TNF) agents are the most commonly used biologic agents. However, some patients may not have an initial response to anti-TNF therapy, and one-third will develop loss of response over time. Here,

Publications
Selected Journal Papers
bottom of page